SciBase receives US patent approval for its micro-needle electrodes
SciBase, a Swedish medtech company that develops and markets a new technology for early detection of malignant melanoma, has received approval from the United States Patent and Trademark Office (USPTO) for its patent on micro-needle electrodes. This technology is already patented in 12 European countries, Australia and Canada. The patent expires 2023.SciBase’s point-of-care device Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies.